TECOS Study With Sitagliptin (Januvia) to Be Reported at ADA TECOS Study With Sitagliptin (Januvia) to Be Reported at ADA
The results of the long-awaited cardiovascular-outcomes trial with Merck's type 2 diabetes treatment, the DPP-4 inhibitor sitagliptin, will be revealed at the American Diabetes Association meeting. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Januvia | Merck | Study